Anti-Lewis Y anti-idiotypic antibodies and uses thereof

An anti-idiotypic antibody and anti-idiotype technology, applied in the field of molecular biology, can solve the problem of undetectable HAHA immune response
CN1867587AInactive Publication Date: 2006-11-22WYETH LLC +1
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
WYETH LLC
Publication Date
2006-11-22
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

This invention provides anti-idiotype antibodies specific for Anti-Lewis Y monoclonal antibodies. The present invention also directed against an ELISA screening method of mAbs produced by hybridoma clones for specific binding to the variable regions of hu3S193 and the ability of the anti-idiotypic mAB to inhibit hu3S193 binding to Lewis Y antigen. Additionally, the present invention provides a hybridoma capable of producing an anti-idiotype antibody specific for anti-Lewis Y monoclonal antibody. A further aspect of the invention is to provide a hybridoma, which is specific for anti-Lewis Y monoclonal antibody selected from the group consisting of LMH-1, LMH-2, LMH-3, or LMH-4. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses using the antibody of the invention.
Need to check novelty before this filing date? Find Prior Art

Description

field of invention

[0001] The present invention relates to the field of molecular biology, more particularly to antibodies. Background of the invention

[0002] The advent of monoclonal antibody (mAb) technology 25 years ago provided a wealth of useful research reagents and created opportunities to use antibodies as approved reagents in cancer therapy, autoimmune disorders, transplant rejection, antiviral prophylaxis, and as antithrombotic agents ( Glennie and Johnson 2000). Using molecular engineering to convert murine mAbs into chimeric mAbs (mouse V-region, human C-region) and humanized reagents, where only the murine mAb complementarity-determining regions (CDRs) are critical for the clinical success of mAb therapy . Engineered mAbs have significantly reduced or lost immunogenicity, increased serum half-life and the human Fc portion of the mAb has increased ability to recruit complement and cytotoxic cellular immune effectors (Clark 2000). Studying the biodistribution...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More